SEPTEMBER 2007
Pharma's Indian challenge
Novartis is fighting a battle in India over the patentability of Glivec. Managing IP analyzes the impact of the case on the international pharmaceutical industry
|
| Representatives from MSF hand in their petition to Novartis |
On paper, Asia has much to offer pharmaceutical companies: highly trained, low-cost scientists to help them develop new blockbuster drugs at a time when many of their most lucrative products are coming off-patent; and a burgeoning middle class whose affluent lifestyles are increasingly likely to make them succumb to ailments and illness that require treatment from products such as cholesterol-lowering drugs and heart disease pills.
The rest of this article is available to subscribers only. Subscribe today for full access to this article.
Alternatively take a free trial, giving you access to the current issue's contents*
If you are already a subscriber, please log in below to access the rest of this article.
*excludes some surveys and articles.